Feed FGR.PA
FG

Eiffage

FGR.PA · PAR

100.10 € +0.54% (+0.54 €)
1M -8.08%
Market Cap 10.5B €
P/E Ratio 10.28x
Div. Yield 4.48%
ROE 14.20%

Bulios Fair Price

113.09 €

13.0% upside

Current Price

100.1 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, FGR.PA is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Moderate
6/9
Valuation
100 /100
Cheap
EV/EBITDA 5.10x
P/S 0.40x
P/B 1.40x
Growth
50 /100
Stable
Rev. growth 7.77%
FCF growth 3.63%
Book val. growth 6.69%
Profitability
42 /100
Moderate
Net margin 3.91%
Op. margin 9.97%
FCF margin 10.79%
Quality
45 /100
Average
ROE 14.20%
ROA 2.50%
Asset turnover 0.64x
Debt
38 /100
Moderate
Current ratio 0.95x
Int. coverage 6.12x
Net debt/EBITDA 2.60x
Stability
100 /100
Stable
Rev. volatility 0.85%
EPS volatility 6.27%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about FGR.PA
Online

About the company

Eiffage SA is a French construction and engineering company headquartered in Paris, specializing in the construction of infrastructure projects, including roads, railways, bridges, tunnels, and buildings. The company focuses on sustainability and innovation in construction and provides solutions for both public and private investments. Eiffage operates not only in France but also in international markets.

Sector

Industrials

Industry

Engineering & Construction

CEO

Benoit de Ruffray

Employees

87,000

Headquarters

Vélizy-Villacoublay

Upcoming events

24 FEB

Earnings

Upcoming earnings report

143d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.